Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026
Mineralys Therapeutics presented late-breaking Transform-HTN open-label extension data at AHA Scientific Sessions 2026, showing lorundrostat sustained a 17.8 mmHg reduction in automated office systolic blood pressure through Week 48. Fifty-six percent of participants reached systolic blood pressure below 130 mmHg, and the drug was well tolerated with no new clinically relevant safety findings versus the parent Launch-HTN trial.
Key figures
- Drug Name
- lorundrostat
- Phase Of Trial
- Phase 3 (Launch-HTN) with open-label extension (Transform-HTN)
- Pdufa date
- 2026-12-22
- Safety analysis n
- 632
- Efficacy analysis n
- 504
- Followup completion pct
- 92%
- Treatment related sae pct
- 0.3%
- Serious adverse events pct
- 4.3%
- Discontinuation due to ae pct
- 5.9%
- Pct achieving aosbp below 130
- 56.0%
- Hyperkalemia dose modification pct
- 5.1%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.